New combo therapy aims to tame tough Crohn's cases
NCT ID NCT03219359
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study is for people with active Crohn's disease that hasn't improved with standard treatments. Participants will receive a stem cell transplant followed by a drug called vedolizumab to help keep the disease in remission. The goal is to see if this combination can reduce symptoms and improve quality of life for up to a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?